Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $178.64.

RGEN has been the topic of several recent research reports. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st.

Repligen Price Performance

RGEN opened at $137.12 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $7.70 billion, a P/E ratio of -268.86, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company’s 50 day simple moving average is $154.75 and its 200-day simple moving average is $148.22. Repligen has a one year low of $113.50 and a one year high of $187.25.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts anticipate that Repligen will post 1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC raised its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $29,000. Raiffeisen Bank International AG bought a new stake in shares of Repligen in the fourth quarter worth $29,000. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the third quarter worth $37,000. Finally, Quarry LP boosted its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.